Member Info for LTbeliever

Given that we already knew about shipments to UK, India and China BUT on the 4th November there was mention (first time, PLEASE correct me if mistaken) of USA-based field trials too, could one assume that the "Government" is the US Government? They wouldn't say "Administration" because that would be too revealing, right?

And talking about Helium, here is their latest portfolio report, at Sept end - they spin a good story about MSYS!
https://www.mrbpartner.ch/media/helium_rising_stars_fund_2021_09.pdf

And back in January, their Presentation - at the time, they held 14% in DVRG so maybe this is why they keep selling down MSYS?
https://www.mrbpartner.ch/media/helium_rising_stars_fund_presentation_january_2021_.pdf

https://iigplc.com/wp-content/uploads/2021/01/IIG-Microsaic-Investment-RNS-25-01-21.pdf
From the above, they got 250 mln shares in January 2021- so, this is the first time they have reduced their stake.
Therefore, Helium being the main culprit for selling remains our main hypothesis!

https://www.irishtimes.com/business/technology/deepverge-awarded-750-000-grant-to-detect-covid-19-in-wastewater-1.4719838
"While the existing retrofitted detection instruments are “the size of fridges”, the intention is to develop instruments of varying size, with some suitable for lowering down manholes."
Mass production, low cost, more sales, more service revenues for MSYS too, and hopefully we will start reading about MSYS in the UK press in 2022!

As per last paragraph (p.2) of DVRG's Broker Note:
Recognising the scale of the opportunities now being presented --
Today’s news follows hot on the heels of last week’s €480,000 order from an unnamed government for DeepVerge’s newly
enhanced monitoring equipment as part of an extended performance trial announcement. Shortly before that, there was £2.2m of Microtox® PD shipments to the UK, India and China in order to meet obligations for delivery in this year. With works now underway...., with potential for ongoing upgrades ..., while also preparing for its mass production in order to satisfy delivery schedules from governments that are expected to demand rapid installation by their utilities across domestic water/wastewater systems, 2022 is expected to witness the start of a step-change in both revenues and demand for Modern Water equipment.
https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/822ed619-6bf1-a3d8-a85e-606a76a57e1f/Deepvergeplc_Research_Update_4November2021__FINAL_BG.pdf

NewU,

You will be glad to know that, NO, the options are unrelated.
The options can be exercised at 30p and their value emanates from the fact that the option-holder can exercise it just prior to expiry. If at expiry (date of which I cannot see in the RNS), say in 2-3 years time, the SP is 90p, then by exercising they make 60p per share; that's their gain and the value inherent in each option.
If the SP is 29p at expiry, they simply would not exercise.

sorry, FIELD trials!
Imagine the servicing revenue from monitoring water quality in hundreds of installations.

filed trials "shortly to bear fruit" in the USA (first time!), UK, China and India.
Mass production for Microtox PD, to go into hospitals, offices, schools etc!

https://www.investegate.co.uk/deepverge-plc--dvrg-/rns/grant-supports-deepverge-centre-of-excellence/202111040700032825R/
Glenn Tracey CEO of Microsaic Systems commented :
We are pleased with progress over the last 10 months working with Modern Water and in particular of being part of the growing centre of excellence between York and Fermoy. The work will shortly bear fruit with our micro-engineered mass-spec[ix] equipment being installed in field trials for eight forever chemicals (PFAS) in US, UK, China and India. These initial 8 detections give us data and proof points that suggest our tech can relentlessly expand to detect hundreds, if not thousands, of other bad actors that make up the family of Forever Chemicals and Contaminants of Emerging Concern in our waterways"

308
I wouldn't say that the churn is coming to an end, but we can be positive when new players are ready and willing to get that 1% off Helium's hands; trades took place yesterday so we will see tomorrow what happens; but things are moving in the right direction.
I beg to differ, SP will rise not just from Microtox BT but also news re China, Bioprocessing, Water mon. installations etc.
All these will build a steady revenue stream with profit margins of 60-70%+.

Pieces are falling into place slowly but surely - from this March 24th RNS (DVRG), which makes much more sense now:
https://www.investegate.co.uk/deepverge-plc--dvrg-/rns/3-year-technology---comm-l-agreem-t-with-microsaic/202103240700152548T/
"DeepVerge will introduce AI data analytics into Microsaic's existing Mass Spectrometry data capture capabilities to fast track the MicrotoxBT breathalyser, which is used to detect the Spike Protein of the SARS-CoV-2 virus, to deliver a "Point of Care" diagnostic solution at the GP's clinic. With biomarker binding agents capable of detecting up to 40 diseases on the human breath, many of which include cancer, neurodegenerative, respiratory and metabolic conditions, it has the potential to enable swift referral for serious conditions and at the same time reduce unnecessary doctor-to-hospital referrals and over-prescription of antibiotics, potentially dramatically lowering healthcare costs."
Maybe an RNS update in November, given that GJB expects full approval by Y/E 2021 (as per DVRG's Final Results' RNS of 30th June):
"Subject to successful completion of additional human trials, the Microtox BT would be expected to meet the criteria for UK, MHRA's Target Product Profile Rapid Breath Test with potential roll out of COVID-19 and other pathogen breath tests later this year ".
GLA, DYOR

1. SP up 10% despite the 10mln share lot sale at 0.18, indicating that the market can now (hopefully) absorb such lots with less impact on the SP;
2. the Broker Note promises more to come, soon (I quote) for DVRG and some will relate to MSYS:
- "...in expectation of a number of further significant news releases between now and the year end..."
- "..Having successfully demonstrated its ability to target single pathogens using nano-optofluidic chips, multiplex version trials are presently underway using the same configuration in order to offer a comprehensive, upgradeable full-time pathogen/virus surveillance as future needs arise. The Group’s subsequent partnership with Microsaic provided for an accelerated miniaturisation of micro-engineering elements that will further enhance the service offerings for multiplex testing of multiple pathogens on the same microchips."
- "Developments presently underway cover 4 iterations including at least 2 further pathogen bindings (possibly Norovirus and pepper mild mottle virus (‘PMMoV’)), while existing bindings have also demonstrated the ability to capture/detect cancerous cells in benchtop equipment testing, making way for clinic diagnostic solutions transferring to point-of-need from hospital ER to GP clinics."...I think this must be related to the recent DIGITAL HEALTH Tweet by GJB (for GPs).

2 important points from the Broker Note:
a) DVRG will be producing c200 MicrotoxPD units per MONTH, within 5-6 months;
b) more MicrotoxPD units already installed/being tested in European locations (so more news to be announced in due course).

https://www.lse.co.uk/rns/DVRG/microtox174-pd-installations-as-part-of-natl-trial-6g7nxtrylwyfhf8.html

306,
I think you are overestimating the overhang IMHO.
10m is c100% of shares but so far, it's mostly Helium that's been a net seller (from 13+% to probably below 7% now).
If we add some HNW clients of TP and some Institutional Investors topslicing, plus short term traders, I don't think that available shares for a quick sale would exceed 30-40% of SCap i.e. £3-4 million, or say 2 bln shares.
By the time that the SP starts to steadily rise (H1 2022 by my estimate), not all of them will have sold out anyway, so they may hang around for the ride!

g306,
it's like a huge dam (the overhang of shares holding the SP back); each RNS creates a small crack, a few more and sometime in 2022 the "dam" will burst and the SP will start rising unhindered.

https://www.bbc.com/news/uk-politics-59052995

As a quick reminder (and included in Investor Presentations), MSYS has already a relationship with:
PFIZER, MERCK, CORNING, SAMSUNG
Just imagine the SP impact an RNS announcing Pfizer (and/or the others) as a Bioprocessing client, in a few months.

I did say "2 RNSs expected per month", back in September.
Anyway, this is not a contract announcement unfortunately BUT it does prepare the ground for 2022 whilst raising further MSYS market profile.

DJB,
Yes, I am aware of that; I mentioned a few times before that this selling by Helium should subside by Q1 2022; 7% sold by them within just 4-5 months is more than 400 mln shares; the market has more or less absorbed these but at the cost of keeping the SP low.
If we all expect however that the SP will be a lot higher in 6-12 months, and/or beyond, we should be availing ourselves (I have, like you) of the opportunity to buy more shares at this low SP.
We don't know why Helium is selling, maybe they are happy to lock into a 100% profit in less than a year; but, as more revenues start pouring in next year, the Mkt is bound to take notice.
DVRG will have a 10m Rev this year, would it be far fetched to say 15-20m next year? Take 10% (min) of this, you get - just from DVRG - 1.5-2 mln Revenues;
Add recurring service fees and spares for the 170+ units already installed (as per Interims' presentation September end), you have another 0.5 mln.
Add China orders (20-30 units?) in 2022, another 1-1.5mln.
Plus Bioprocessing deals, plus extras not valued yet (e.g. cancer in-situ diagnosis), what do we get?
2022 Revenue of 3-4 mln? @60% margin, that's 2-2.5 mln cash i.e. close to annual cash burn.IMHO
Some people may say I am way too optimistic, alI can say is - be patient for another 4-6 months and don't worry about the daily fluctuations; we cannot stop Helium from selling, but we can buy the shares it's selling.
DYOR